Boundless Bio (BOLD) Total Non-Current Liabilities (2024 - 2025)
Boundless Bio (BOLD) posted quarterly Total Non-Current Liabilities of $56.8 million for Q2 2025, up 1.78% quarter-over-quarter from $55.8 million in Q4 2024.
Boundless Bio (BOLD) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
Boundless Bio (BOLD) has reported Total Non-Current Liabilities for 2 consecutive years, with $56.8 million the latest figure, recorded in Q2 2025.
- In Q2 2025, Total Non-Current Liabilities changed N/A year-over-year to $56.8 million; the TTM figure through Jun 2025 stood at $56.8 million (changed N/A YoY), while the FY2024 annual figure was $55.8 million, changed N/A from the prior year.
- Total Non-Current Liabilities grew to $56.8 million in Q2 2025 per BOLD's latest filing, from $55.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $56.8 million in Q2 2025 and bottomed at $55.8 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 9.32 Bn |
| 10 | Boundless Bio | 66.72 Mn | 66.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 56.76 Mn |
| Dec 31, 2024 | 55.77 Mn |